IMNM
Immunome, Inc.
NASDAQ · USHealthcareBiotechnology
$22.16-0.72%
Price as of Jul 20, 2026
IMNM profitability
Immunome, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -1161.9%
- EBITDA margin
- -5523.2%
- EBIT margin
- -5947.9%
- Net margin
- -5593.8%
- Free cash flow margin
- -5118.9%
Returns
- Return on equity
- -38.2%
- Return on assets
- -36.2%
- Return on invested capital
- -40.3%
- Asset turnover
- 0.01x
Cash efficiency
- Cash from operations
- -$196.5M
- Cash per share
- $5.15
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.